NeuroSense Therapeutics Ltd. Logo

NeuroSense Therapeutics Ltd.

A late-clinical stage company developing drugs for neurodegenerative diseases like ALS.

NRSN | US

Overview

Corporate Details

ISIN(s):
IL0011809592 (+1 more)
LEI:
Country:
United States of America
Address:
11 HAMENOFIM ST., 4672562 HERZLIYA

Description

NeuroSense Therapeutics Ltd. is a late-clinical stage drug development company focused on discovering and developing treatments for severe neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS). The company's strategy is to create combined therapies that target multiple pertinent mechanisms involved in these complex conditions. Its lead drug candidate, PrimeC, is a unique fixed-dose combination of ciprofloxacin and celecoxib. Following a successful Phase 2b clinical trial (PARADIGM) that demonstrated a significant impact on slowing disease progression, NeuroSense is advancing PrimeC into a pivotal Phase 3 study. PrimeC has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company is also exploring therapies for other neurodegenerative diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all NeuroSense Therapeutics Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NeuroSense Therapeutics Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NeuroSense Therapeutics Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Bone Biologics Corp Logo
Develops a protein-based bone graft substitute for spinal fusion procedures.
United States of America
BBLG
Bonyf N.V. Logo
Develops medical devices for oral, dental, orthodontic, and dermatological care.
Belgium
MLBON
Boryung Corporation Logo
A healthcare company developing pharmaceuticals and investing in health sector innovation.
South Korea
003850
Bosnalijek d.d. Sarajevo Logo
Develops, manufactures, and exports a wide range of pharmaceutical products.
Bosnia and Herzegovina
BSNL
Boule Diagnostics Logo
Provider of hematology systems for decentralized human and veterinary markets.
Sweden
BOUL
Boundless Bio, Inc. Logo
Clinical-stage oncology company targeting ecDNA in oncogene amplified cancers.
United States of America
BOLD
BridgeBio Oncology Therapeutics, Inc. Logo
Clinical-stage biopharma developing inhibitors for genetically driven cancers.
United States of America
BBOT
BridgeBio Pharma, Inc. Logo
Develops transformative medicines for genetic diseases and cancers.
United States of America
BBIO
BRIGHT MINDS BIOSCIENCES INC. Logo
Develops selective serotonin agonists for neurological and psychiatric disorders.
United States of America
DRUG
A clinical-stage biopharma company developing cancer immunotherapies and cell therapies.
Japan
4594

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.